Regenxbio Inc (RGNX)

Activity ratios

Short-term

Turnover ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Inventory turnover — 10.96 9.01 8.82 10.54 9.99 9.49 8.02 7.10 6.04 8.55 7.51 9.42 5.95 7.16 8.75 8.94 7.89 8.07 6.62
Receivables turnover 3.45 3.19 3.87 4.76 3.19 12.16 11.32 16.02 13.77 2.93 6.20 6.66 6.30 2.14 2.22 1.60 1.16 3.83 5.67 10.39
Payables turnover 6.05 6.30 11.70 5.88 5.38 5.87 9.08 6.02 11.70 5.60 11.97 9.19 9.32 6.29 6.40 7.21 9.03 5.68 8.32 9.91
Working capital turnover 0.42 0.38 0.32 0.32 0.31 1.26 1.21 1.32 1.15 0.44 0.80 0.66 0.60 0.81 0.33 0.23 0.14 0.22 0.16 0.31

The activity ratios provide insights into Regenxbio Inc's efficiency in managing its various operating assets and liabilities.

1. Receivables Turnover:
- The receivables turnover ratio measures how efficiently the company is collecting payments from its customers.
- The trend indicates that Regenxbio Inc's receivables turnover has been fluctuating over the past eight quarters, with a decrease seen in Q4 2023 compared to the previous quarter.
- A higher ratio is generally preferable as it implies faster collection of receivables, translating into improved cash flow.

2. Payables Turnover:
- The payables turnover ratio gauges how quickly the company pays its suppliers and creditors.
- The data shows variability in the payables turnover ratio, with a significant decrease observed in Q3 2023 followed by a partial recovery in Q4 2023.
- A lower payables turnover ratio could indicate that the company is taking longer to pay its bills, potentially affecting supplier relationships.

3. Working Capital Turnover:
- The working capital turnover ratio assesses how efficiently the company is utilizing its working capital to generate sales.
- There is a declining trend in Regenxbio Inc's working capital turnover over the past two years, indicating a decrease in revenue generation relative to its working capital levels.
- A higher working capital turnover ratio is preferred as it signifies effective utilization of resources to drive sales.

Overall, in-depth analysis of these activity ratios would be crucial to understanding Regenxbio Inc's operational efficiency and financial health in managing its assets and liabilities.

Average number of days

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Days of inventory on hand (DOH) days — 33.30 40.49 41.40 34.62 36.54 38.46 45.53 51.38 60.44 42.70 48.61 38.74 61.36 50.97 41.73 40.83 46.28 45.25 55.11
Days of sales outstanding (DSO) days 105.72 114.28 94.21 76.69 114.56 30.02 32.24 22.79 26.51 124.66 58.83 54.80 57.89 170.51 164.24 228.39 313.50 95.32 64.41 35.12
Number of days of payables days 60.29 57.95 31.19 62.11 67.78 62.15 40.21 60.67 31.20 65.18 30.51 39.73 39.17 58.05 56.99 50.65 40.42 64.26 43.87 36.82

Days of inventory on hand (DOH) data is missing in the table, which hinders a complete analysis of Regenxbio Inc's inventory management efficiency.

Days of sales outstanding (DSO) witnessed a fluctuating trend over the quarters, indicating variability in the company's ability to collect receivables. The DSO increased from 24.75 days in Q3 2022 to 103.00 days in Q3 2023, which suggests a potential issue with collecting payments within a reasonable timeframe.

The number of days of payables also exhibited fluctuation, with varying payment terms agreed upon by Regenxbio Inc with its suppliers. Notably, the number of days of payables increased significantly from 97.76 days in Q2 2022 to 223.49 days in Q4 2023, possibly indicating a change in the company's payment strategy or cash flow management approach.

Overall, Regenxbio Inc may need to focus on optimizing its accounts receivable collection processes and managing its payment terms effectively to improve liquidity and working capital management.

Long-term

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Fixed asset turnover 0.65 0.66 0.60 0.63 0.63 2.81 3.06 3.20 3.40 1.10 2.58 3.06 4.80 6.73 2.91 2.34 1.53 2.60 2.01 3.76
Total asset turnover 0.15 0.14 0.12 0.12 0.11 0.45 0.45 0.42 0.40 0.17 0.33 0.31 0.38 0.48 0.21 0.15 0.09 0.14 0.10 0.17

The fixed asset turnover ratio for Regenxbio Inc has been showing a decreasing trend over the past eight quarters, indicating that the company is generating less revenue from its fixed assets. This could be a cause for concern as it suggests a decline in the efficiency of using its long-term assets to generate sales.

On the other hand, the total asset turnover ratio has remained relatively stable, albeit low, over the same period. This ratio indicates the company's ability to generate sales relative to its total assets. A low total asset turnover may signal inefficiency in asset utilization or a large proportion of non-operating assets on the company's balance sheet.

Overall, the declining trend in fixed asset turnover combined with the consistently low total asset turnover suggests that Regenxbio Inc may need to review its asset management strategies to improve efficiency in utilizing both fixed and total assets in generating revenue. Further analysis and comparison with industry benchmarks may provide more insights into the company's performance in this area.